The Latest Cardiac and Vascular News
SANTA CLARA, Calif.–(BUSINESS WIRE)–HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights wherever the patient is, announced the appointment of Timothy Cruickshank as Chief Financial Officer (CFO), effective immediately. Mr. Cruickshank brings more than 15 years of public company experience with […]
BAAR, Switzerland–(BUSINESS WIRE)–CorFlow Therapeutics AG (CorFlow) announced today that it has raised €44 million in Series B funding, co-led by Broadview Ventures and Panakes Partners with strong continued support from 415 Capital, CorFlow’s initial VC investor and largest shareholder. Merieux Equity Partners, Laerdal Million Lives Fund, Wellington Partners, M&L Investments, Unorthodox Ventures, KOFA Healthcare and Monte Carlo Capital participated in the multinational syndicate. “The improvement in […]
Laminate Medical Technologies Thanks Kidney Patients for Advocacy NEW YORK, Sept. 10, 2024 /PRNewswire/ — Laminate Medical Technologies today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) granted their VasQ™ extravascular support device a Transitional…
Funding Will Support Clinical Studies of the VelocityTM pAVF System in Patients with Chronic Kidney and End-Stage Renal Disease (Los Gatos, California) – Venova Medical, Inc. (Venova Medical), a privately held company developing a next generation technology for the creation of percutaneous arteriovenous fistulas (pAVF) for hemodialysis access today announced the […]
WEST VALLEY CITY, Utah, Sept. 9, 2024 /PRNewswire/ — Scientia Vascular, a leader in neurovascular innovation, is pleased to announce the closing of a $14 million growth financing led by Piper Sandler Merchant Banking. The financing will enable Scientia to continue commercializing the…
Half-year sales of €3.3 million, exceeding 2023 full-year sales 20 implants of the Aeson® artificial heart performed in the first half of 2024 17% cash-burn1 reduction compared to the first half of 2023 2024 anticipated annual sales of €8 to €12 million Other 2024 operational objectives on track Active exploration of […]
New vice president of clinical affairs and board of directors member will support advancement of eLym™ System therapy for acute decompensated heart failure GALWAY, Ireland — September 5, 2024 — WhiteSwell, a company pioneering a new paradigm in the treatment of acute decompensated heart failure (ADHF), today announced the appointments of Ric Cote to […]
Medera is a clinical-stage biotechnology company focused on targeting difficult-to-treat cardiovascular diseases using a range of next-generation gene- and cell-based approaches in combination with bioengineered human mini-heart drug discovery and screening technology platforms…
New partnership delivers critical insights to more cardiovascular care teams to identify and define atherosclerosis earlier SAN FRANCISCO – September 4, 2024 — Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, and Cleerly, the company working to create a new standard of care for the diagnosis of heart […]
MONTREAL and CHARLOTTE, N.C., Sept. 04, 2024 (GLOBE NEWSWIRE) — Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the appointment of Joseph Papa to its Board of Directors (“Board”), effective September 3, 2024.
